It became a trader stock lately, so moves won't be based on fundamentals. And there are also warrants at lower price and I saw many times how the stock run up and down during warrant plays.
Your complaint about no published ORR is valid, but it seems this is one of the endpoints for Phase II so you will have to wait until the second half of the year.
Here is a slide from their most recent presentation:
Copied from the transcript of their most recent conference call:
"The Phase 2 study will be conducted in up to 15 centers across the United States. We expect that all patients will receive a single dose of CLR 131 at 25 mCi/m2 infused over approximately 30 minutes, with the option of a second dose occurring between 75 and 180 days later, based upon physician assessment.
Currently, those patients in the trial with multiple myeloma will also be receiving 40 milligrams, I'm sorry about that. Concurrently, those patients in the trial with multiple myeloma will also be receiving 40 mg oral dexamethasone weekly for up to 12 weeks. The primary endpoint for the study is Objective Response Rate or ORR; secondary endpoints include progression-free survival, median overall survival and other measures of efficacy. In relapsed/refractory multiple myeloma patients' efficacy responses will be determined according to the latest International Multiple Myeloma Working Group Criteria, while those in the lymphoma arms, efficacy will be determined according to the Lugano criteria."
News 
Market Data 
Discover 
